Sectral (acebutolol HCl) is a selective, hydrophilic beta-adrenoreceptor blocking agent with mild intrinsic sympathomimetic activity for use in treating patients with hypertension and ventricular arrhythmias.
Sectral (acebutolol HCl) is indicated for the following:
Sectral is indicated for the management of hypertension
in adults. It may be used alone or in combination with other
antihypertensive agents, especially thiazide-type diuretics.
Sectral is indicated in the management of ventricular
premature beats; it reduces the total number of premature beats,
as well as the number of paired and multiform ventricular
ectopic beats, and R-on-T beats.
Published Studies Related to Sectral (Acebutolol)
[The comparison of clinical effectiveness of perindopril and acebutolol in the primary hypertension treatment] 
Hypertension is one of the most important risk factors for ischaemic heart disease and stroke. The aim of our study was to assess the antihypertensive effect of angiotensine converting enzyme inhibitor (perindopril) versus beta blocker (acebutolol) in hypertensive patients... After 3 weeks of the treatment we observed BP systolic and diastolic normalization, but more patients had systolic BP normalization after perindopril treatment.
Selectivity of acebutolol, atenolol, and metoprolol in healthy volunteers
estimated by the extent the drugs occupy beta 2-receptors in the circulating
The selectivity of acebutolol, atenolol, and metoprolol in healthy volunteers was
estimated by determining the extent to which the drugs occupied beta 1-receptors
of rabbit lung and beta 2-receptors of rat reticulocytes in the circulating
plasma after drug intake.The receptor occupancy of the agents was well in agreement with the
literature concerning the selectivity, intensity, and time-course of drug actions
after identical doses.(ABSTRACT TRUNCATED AT 250 WORDS).
Acebutolol effects on lipid profile. 
The relation between lipid profile and the incidence of coronary artery disease
has been confirmed by the results of epidemiologic and intervention studies. Among antihypertensive agents, beta blockers, particularly those without
intrinsic sympathomimetic activity (ISA), are generally reported to have negative
effects on lipids, which may increase the risk of coronary artery disease.
Efficacy of acebutolol after acute myocardial infarction (the APSI trial). The
APSI Investigators. 
A randomized, placebo-controlled trial was carried out to determine the
effectiveness of acebutolol in preventing late death in high-risk patients
surviving an acute myocardial infarction (MI). The average 1-year mortality rate
in placebo groups of 9 trials of beta blockers in post-MI patients was 7.2%
compared with 17% in a nonselected cohort of patients who had survived at least 7
days after an MI...
Comparison of the antihypertensive effects of celiprolol and acebutolol. 
The antihypertensive effects of the new cardioselective beta-blocker celiprolol and acebutolol have been compared. Thirty patients with arterial hypertension WHO Grade I-II were treated in a double-blind fashion with celiprolol or acebutolol... The decrease in diastolic blood pressure at the end of the second week was significantly correlated with the reciprocal of the plasma celiprolol concentration at steady-state at the end of the dosage interval.
Clinical Trials Related to Sectral (Acebutolol)
Kangaroo Mother Care to Prevent Hypothermia in Term Infants [Recruiting]
The overall hypothesis is that better adherence to Kangaroo Mother Care (KMC) in combination
with existing WHO thermoregulation care will reduce the incidence of moderate hypothermia
(32-36 degrees C) or severe hypothermia (<32. 0 degrees C) in term infants (greater than or
equal to 37 weeks of gestational age) when compared with routine WHO thermoregulation alone.
Reports of Suspected Sectral (Acebutolol) Side Effects
Confusional State (6),
Lactic Acidosis (4),
Electrocardiogram QRS Complex Prolonged (4),
Renal Failure Acute (4),
Rash Papular (4),
Hypotension (3), more >>
Page last updated: 2013-02-10